Celadon Pharmaceuticals PLC Result of AGM (3678Q)
28 June 2022 - 3:15AM
UK Regulatory
TIDMCEL
RNS Number : 3678Q
Celadon Pharmaceuticals PLC
27 June 2022
Celadon Pharmaceuticals Plc
("Celadon" or the "Company")
Result of Annual General Meeting
London, UK, 27 June 2022 : Celadon Pharmaceuticals Plc (AIM:
CEL), a UK-based pharmaceutical company focused on the development
and supply of natural, cannabis-based medicines, announces that at
its Annual General Meeting held today, all resolutions were duly
passed.
Full details of the poll results will shortly be set out on the
Company's website , along with Celadon's recent Business Update,
which was published on 22 June 2022 .
Enquiries:
Celadon Pharmaceuticals Plc
James Short Via Powerscourt
Arthur Wakeley
Canaccord Genuity Limited (Nominated
Adviser and Broker)
Andrew Potts / Patrick Dolaghan +44 (0) 20 7523 8000
Powerscourt Group
Sarah MacLeod / Nick Johnson / Sam Austrums +44 (0) 20 7250 1446
/ celadon@powerscourt-group.com
Ibrahim Khalil
About Celadon Pharmaceuticals Plc
Celadon Pharmaceuticals Plc is a UK based pharmaceutical company
focused on the research, cultivation, manufacturing, and supply of
natural cannabis-based medicines. Its primary focus is on improving
quality of life for chronic pain sufferers, as well as exploring
the potential of cannabis-based medicines for other conditions such
as autism. Its 100,000 sq ft UK facility comprises a laboratory
designed to meet GMP standards, and capacity for a large indoor
hydroponic growing facility that has received a Home Office Licence
for the legal cultivation of high-THC medicinal cannabis for the
purpose of producing test batches of cannabis oil to support its
application to the MHRA. The Company's subsidiary, LVL, owns an
MHRA conditionally approved cannabis trial using cannabis based
medicinal products to treat chronic pain in the UK.
For further information please visit our website
www.celadonpharma.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
RAGBKOBKOBKDCAB
(END) Dow Jones Newswires
June 27, 2022 13:15 ET (17:15 GMT)
Celadon Pharmaceuticals (LSE:CEL)
Historical Stock Chart
From Apr 2024 to May 2024
Celadon Pharmaceuticals (LSE:CEL)
Historical Stock Chart
From May 2023 to May 2024